Hydroxychloroquine in coronavirus disease 2019 patients: What still needs to be known about the kinetics

Guillaume Martin-Blondel; Stéphanie Ruiz; Marlène Murris; Stanilas Faguer; Véronigue Duhalde; Frédéric Eyvrard; Jacques Izopet; Jean Michel Mansuy; Yves Rolland; Karen Delavigne; Rosine Guimbaud; Grégory Pugnet; Jean Marie Conil; Bernard Georges; Pierre Delobel; Vincent Minville; Stein Silva Sifontes; Didier Concordet; Peggy Gandia

Journal ArticleOPEN ACCESS

Hydroxychloroquine in coronavirus disease 2019 patients: What still needs to be known about the kinetics

Clinical Infectious Diseases (2020) 71(11) 2962-2964

DOI: 10.1093/cid/ciaa558

10Citations

86Readers

Get full text

Abstract

Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations.

Author supplied keywords

Cite

CITATION STYLE

APA

Martin-Blondel, G., Ruiz, S., Murris, M., Faguer, S., Duhalde, V., Eyvrard, F., … Gandia, P. (2020). Hydroxychloroquine in coronavirus disease 2019 patients: What still needs to be known about the kinetics. Clinical Infectious Diseases, 71(11), 2962–2964. https://doi.org/10.1093/cid/ciaa558

Hydroxychloroquine in coronavirus disease 2019 patients: What still needs to be known about the kinetics

Abstract

Author supplied keywords

Cite

Register to see more suggestions